Posted by Michael Wonder on 01 Nov 2022
Verzenio (abemaciclib) receives positive reimbursement recommendation from CADTH for early breast cancer
1 November 2022 - Lilly Canada announced today that CADTH has issued their final reimbursement recommendation for Verzenio (abemaciclib) in early breast cancer.
CADTH recommends that Verzenio in combination with endocrine therapy be reimbursed for the adjuvant treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ≥20%.
